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AbstrAct
Progressive ataxia in adults can be difficult to 
diagnose, owing to its heterogeneity and the 
rarity of individual causes. Many patients remain 
undiagnosed (‘idiopathic’ ataxia). This paper 
provides suggested diagnostic pathways for 
the general neurologist, based on Ataxia UK’s 
guidelines for professionals. MR brain scanning 
can provide diagnostic clues, as well as identify 
‘structural’ causes such as tumours and multiple 
sclerosis. Advances in molecular genetics, 
including the wider and cheaper availability of 
‘next-generation sequencing’, have enabled 
clinicians to identify many more cases with a 
genetic cause. Finally, autoimmunity is probably 
an under-recognised cause of progressive 
ataxia: as well as patients with antigliadin 
antibodies there are smaller numbers with 
various antibodies, including some associated 
with cancer. There are a few treatable ataxias, 
but also symptomatic treatments to help 
people with the spectrum of complications 
that might accompany progressive ataxias. 
Multidisciplinary team involvement and allied 
health professionals’ input are critical to excellent 
patient care, including in the palliative phase. We 
can no longer justify a nihilistic approach to the 
management of ataxia.
IntroductIon
Ataxia, or lack of coordination, is a 
common manifestation of various neuro-
logical conditions, including stroke, brain 
tumour, multiple sclerosis, traumatic 
brain injury, toxicity, infection (including 
following varicella) and congenital cere-
bellar defects. Its evolution can be acute, 
subacute, episodic or chronic. Progressive 
ataxias frequently cause diagnostic uncer-
tainty in general neurological practice, 
and many cases remain undiagnosed (or 
‘idiopathic’). This review aims to provide 
general neurologists with helpful path-
ways for diagnosing and managing adults 
with progressive ataxias. Recent advances 
in molecular genetics have enabled the 
diagnosis of many more cases with a 
genetic cause. Autoimmunity may also 
be important (but under-recognised) 
in causing some progressive cerebellar 
ataxias. There are no current treatments 
to halt the progression of most forms of 
chronic ataxia (with a few notable excep-
tions) but there have been recent advances 
in disease-modifying interventions. Ataxia 
management warrants a broad and multi-
disciplinary approach.
In this review, we explore in detail the 
progressive ataxias in adults, providing 
guidance on how to diagnose and to 
manage patients (and their families). Our 
advice is based on Ataxia UK’s guide-
lines on the management of the ataxias 
(third edition July 2016), to which we 
have contributed (https://www. ataxia. 
org.  uk/  Handlers /  Download.  ashx? 
IDMF= 261e0aa4- 5ca0- 4b90- 9db0- 
1ecb6ef8738a).1 Our emphasis is clinical, 
guiding the busy general neurologist to 
a precise diagnosis, identifying pitfalls 
to avoid and outlining best practice in 
managing patients.
types of ataxia
The ataxias may be broadly divided into 
those that are genetic (with or without 
a family history) and those that are 
acquired/degenerative. ‘Sporadic’ ataxia 
implies there is no family history. Acquired 
progressive ataxias can be immune medi-
ated (eg, paraneoplastic spinocerebellar 
degeneration, gluten ataxia), degenerative 
(eg, cerebellar variant of multiple systems 
atrophy (type C)), caused by deficiency 
states (eg, vitamin B12, vitamin E, and so 
on), toxicity (eg, alcohol-related ataxia, 
phenytoin), or associated with infections 
(HIV, sporadic Creutzfeldt-Jakob disease, 
progressive multifocal leucoencephalop-
athy, and so on). Inherited ataxias can have 
autosomal dominant, autosomal recessive, 
X-linked or mitochondrial (maternal) 
inheritance. Metabolic disorders (eg, 
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Niemann-Pick type C, Tay-Sachs disease), even though 
‘inherited’, can present as late-onset ataxia with no 
family history, emphasising the need for careful clin-
ical scrutiny and comprehensive and appropriate labo-
ratory testing.
clinical presentation
Patients with ataxia report clumsiness, unsteadiness, 
incoordination and slurred speech. Rarely, they expe-
rience oscillopsia. When examined, there may be one 
or more of the following signs2:
 ► Gait ataxia and impaired sitting balance (usually late in 
the disease).
 ► Gaze-evoked nystagmus, jerky (saccadic) pursuit and 
hypo/hypermetropic saccades.
 ► Dysarthria.
 ► Intention tremor.
 ► Dysmetria.
 ► Dysdiadochokinesis.
The signs rarely indicate the cause of the patient’s 
ataxia but occasionally there are very helpful hints.
 ► Reflexes are usually reduced or absent in Friedreich’s 
ataxia, ataxia associated with vitamin E deficiency, 
ataxia with oculomotor apraxia type 2 and spinocere-
bellar ataxia (SCA) type 2. Reflexes are present, even 
brisk, in patients with most of the dominant SCAs and 
patients with multiple systems atrophy type C.
 ► Eye movements. Oculomotor apraxia can develop in 
ataxia-telangiectasia and in ataxia with oculomotor 
apraxia type 1 (although rare in this condition) and type 
2. Slow saccades are typical of SCA type 2.
 ► Postural hypotension (often with impotence and urinary 
urgency/incontinence) points towards multiple systems 
atrophy type C.
 ► Tendon xanthomas (and early-onset cataracts) suggest 
cerebrotendinous xanthomatosis.
 ► Abnormal visually enhanced vestibulo-ocular reflexes 
(and pathological head impulse test responses) are 
characteristic of cerebellar ataxia with neuropathy and 
vestibular areflexia syndrome (CANVAS), which also has 
a sensory neuropathy/neuronopathy.39
The age of onset and the rate of ataxia progres-
sion are perhaps the two most useful clinical features 
pointing to the cause.
 ► Age of onset. Ataxia may appear first in infancy (reflecting 
a congenital or developmental cause, often genetic) or 
develop before aged 20 years (early-onset ataxia). Most 
early-onset ataxias prove to be genetic (usually auto-
somal recessive or mitochondrial inheritance), even if 
there is no family history. Dominant ataxias (including 
the SCAs) tend to present later (from the third and 
fourth decades onwards). However, this rule does not 
always hold: Friedreich’s ataxia can have a late onset 
(with intact or even brisk reflexes) and also some SCAs 
have very young-onset forms (associated with large CAG 
repeat expansions). CANVAS, despite recessive inher-
itance, presents unusually late (in middle age).39
 ► Rapid progression (within weeks to months) is character-
istic of paraneoplastic spinocerebellar degeneration and 
sporadic Creutzfeldt-Jakob disease. Multiple systems 
atrophy type C can also advance faster than other 
progressive neurodegenerative ataxias (including inher-
ited types), which generally progress over many years.
There are validated measures (such as the ‘scale 
for the assessment and rating of ataxia’, table 1) to 
monitor the rate of progression serially.3 Therapeutic 
trials require researchers to use rating scales, which 
have as their endpoint the improvement or the halting 
of progression of ataxia.
Investigation
Brain imaging with MRI (or CT, if MRI is contrain-
dicated) is essential in almost everyone with ataxia. 
While it is rarely diagnostic, it often provides helpful 
diagnostic clues, as well as ruling out structural 
pathology (table 2). The MR scan usually shows cere-
bellar atrophy, in line with the clinical appraisal.
diagnostic tests
Table 3 shows the investigations useful for patients 
presenting with ataxia, listed as first, second and third 
lines, based on the guidelines.
First-line studies, such as checking thyroid function, 
serum B12 and folate (and homocysteine) and coeliac 
serology, could be undertaken in primary care. Most 
people with ataxia require evaluation in secondary care, 
preferably by a neurologist. At this point, in addition to 
cranial (with/without spinal) imaging, patients may need 
(depending on clinical context) lumbar puncture, elec-
trophysiological testing, CT scan of thorax, abdomen 
and pelvis, and muscle biopsy. Genetic testing (even if 
there is no family history) may also be considered at 
this stage, given how commonly genetic factors cause 
progressive ataxia. Rapid progression of ataxia (within 
months) should prompt a search for underlying malig-
nancy, including with serological testing for parane-
oplastic antibodies.4 A fluorodeoxyglucose positron 
emission tomography study may be indicated, even if the 
CT scan of thorax, abdomen and pelvis is normal. The 
responsible malignancy may be occult and easily missed 
in the initial imaging. Its identification may enable earlier 
diagnosis of the cancer, and possibly cure. Some forms 
of Creutzfeldt-Jakob disease (including inherited forms, 
such as Gerstmann-Straussler syndrome) can present 
with progressive ataxia, when again the tempo of deteri-
oration may be relatively rapid. Neurologists frequently 
infer that alcohol toxicity is causing a patient’s progres-
sive cerebellar ataxia but such cases usually justify 
further investigation, which often identifies alternative/
additional explanations for their ataxia.
Genetic testing
Genetic diagnoses among patients with progressive 
inherited ataxia are still evolving, especially with recent 
rapid advances in molecular genetics. The advent and 
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Table 1 Scale for the assessment and rating of ataxia (SARA)
1. Gait 2. Stance
Proband is asked (1) to walk at a safe distance parallel to a wall 
including a half-turn (turn around to face the opposite direction of gait) 
and (2) to walk in tandem (heels to toes) without support.
0—Normal, no difficulties in walking, turning and walking tandem (up 
to one misstep allowed)
1—Slight difficulties, only visible when walking 10 consecutive steps in 
tandem
2—Clearly abnormal, tandem walking >10 steps not possible
3—Considerable staggering, difficulties in half-turn, but without support
4—Marked staggering, intermittent support of the wall required
5—Severe staggering, permanent support of one stick or light support 
by one arm required
6—Walking >10 m only with strong support (two special sticks or 
stroller or accompanying person)
7—Walking <10 m only with strong support (two special sticks or 
stroller or accompanying person)
8—Unable to walk, even supported
Proband is asked to stand (1) in natural position, (2) with feet together 
in parallel (big toes touching each other) and (3) in tandem (both feet 
on one line, no space between heel and toe). Proband does not wear 
shoes, eyes are open. For each condition, three trials are allowed. The 
best trial is rated.
0—Normal, able to stand in tandem for >10 s
1—Able to stand with feet together without sway, but not in tandem 
for >10 s
2—Able to stand with feet together for >10 s, but only with sway
3—Able to stand for >10 s without support in natural position, but not 
with feet together
4—Able to stand for >10 s in natural position only with intermittent 
support
5—Able to stand >10 s in natural position only with constant support 
of one arm
6—Unable to stand for >10 s even with constant support of one arm
Score Score
3. Sitting 4. Speech disturbance
Proband is asked to sit on an examination bed without support of feet, 
eyes open and arms outstretched to the front.
0—Normal, no difficulties sitting >10 s
1—Slight difficulties, intermittent sway
2—Constant sway, but able to sit >10 s without support
3—Able to sit for >10 s only with intermittent support
4—Unable to sit for >10 s without continuous support
Speech is assessed during normal conversation.
0—Normal
1—Suggestion of speech disturbance
2—Impaired speech, but easy to understand
3—Occasional words difficult to understand
4—Many words difficult to understand
5—Only single words understandable
6—Speech unintelligible/anarthria
Score Score
5. Finger chase 6. Nose–finger test
Rated separately for each side
Proband sits comfortably, if necessary with their feet and trunk 
supported. Examiner sits in front of proband and performs five 
consecutive sudden and fast-pointing movements in unpredictable 
directions in a frontal plane, at about half of proband’s reach. 
Movements have an amplitude of 30 cm and a frequency of one 
movement every 2 s. Proband is asked to follow the movements with his 
index finger, as fast and precisely as possible. Average performance of 
last three movements is rated.
0—No dysmetria
1—Dysmetria, under/overshooting target <5 cm
2—Dysmetria, under/overshooting target <15 cm
3—Dysmetria, under/overshooting target >15 cm
4—Unable to perform 5 pointing movements
Rated separately for each side
Proband sits comfortably, if necessary with their feet and trunk 
supported. Proband is asked to point repeatedly with the index finger 
from his nose to examiner’s finger, which is in front of the proband at 
about 90% of proband’s reach. Movements are performed at moderate 
speed. The average performance of movements is rated according to the 
amplitude of the kinetic tremor.
0—No tremor
1—Tremor with an amplitude <2 cm
2—Tremor with an amplitude <5 cm
3—Tremor with an amplitude >5 cm
4—Unable to perform
5—Pointing movements
Score Right Left Score Right Left
Mean of both sides (R+L)/2 Mean of both sides (R+L)/2
7. Fast alternating hand movements 8. Heel–shin slide
Rated separately for each side
Proband sits comfortably, if necessary, with the feet and trunk 
supported. The proband is asked to perform 10 cycles of repetitive 
alternation of pronations and supinations of the hand on the thigh 
as fast and as precisely as possible. The examiner demonstrates the 
movement at about 10 cycles within 7 s. Exact times for movement 
execution have to be taken.
1. 0—Normal, no irregularities (performs <10 s)
2. 1—Slightly irregular (performs <10 s)
3. 2—Clearly irregular, single movements difficult to distinguish or relevant 
interruptions, but performs <10 s
4. 3—Very irregular, single movements difficult to distinguish or relevant 
interruptions, performs >10 s
5. 4—Unable to complete 10 cycles
Rated separately for each side
Proband lies on examination bed, unable to see his/her legs. Proband 
is asked to lift one leg, point with the heel to the opposite knee, 
slide down along the shin to the ankle, and lay the leg back on the 
examination bed. The task is performed three times. Slide-down 
movements should be performed within 1 s. If proband slides down 
without contact to shin in all three trials, rate 4.
0—Normal
1—Slightly abnormal, contact to shin maintained
2—Clearly abnormal, goes off shin up to three times during three cycles
3—Severely abnormal, goes off shin four or more times during three 
cycles
4—Unable to perform the task
Score Right Left Score Right Left
Mean of both sides (R+L)/2 Mean of both sides (R+L)/2
 o
n
 3 June 2019 by guest. Protected by copyright.
http://pn.bmj.com/
Pract N
eurol: first published as 10.1136/practneurol-2018-002096 on 2 M
ay 2019. Downloaded from
 
199de Silva RN, et al. Pract Neurol 2019;19:196–207. doi:10.1136/practneurol-2018-002096
Review
Table 2 Diagnostic clues from MR scanning of the brain
Condition MR brain scan finding(s) MRI sequence
‘Diagnostic’
Multiple systems atrophy type C ‘Hot-cross bun’ sign*; pontine atrophy (figure 1) T2/FLAIR
Fragile X tremor-ataxia syndrome Middle cerebellar peduncle sign† (figure 2) T2/FLAIR
Superficial siderosis Deposition of haemosiderin; cerebellar atrophy (figure 3) GRE/T2*
Sporadic Creutzfeldt-Jakob disease High basal ganglia signal; cortical high (and persistent DWI) signal T2/FLAIR, DWI/ADC
Autosomal recessive spastic ataxia of Charlevoix-
Saguenay
Hypointense pontine stripes (figure 4); atrophy of superior cerebellar vermis; 
thinning of posterior mid-body of corpus callosum
T2/FLAIR
SPG7 High dentate nuclei signal (figure 5)38 T2/FLAIR
‘Suggestive’ (in familial forms)
Friedreich’s ataxia, vitamin E deficiency Upper cervical cord atrophy; cerebellar atrophy late (figure 6) T1/T2
Ataxia-telangiectasia, ataxia with oculomotor 
apraxia, types 1 and 2
Cerebellar atrophy T1/T2
Autosomal dominant spinocerebellar ataxia Cerebellar and pontine atrophy T1/T2
*Also occurs in autosomal dominant spinocerebellar ataxia.
†Can occur in multiple systems atrophy type C.
ADC, apparent diffusion coefficient; DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion recovery; GRE, gradient echo; SPG7, spastic 
paraplegia 7.
Figure 1 Fluid-attenuated inversion recovery (FLAIR) axial 
image of the brain, showing pontine and cerebellar atrophy, 
and ‘hot-cross bun’ sign, in a patient with multiple systems 
atrophy type C (MSA-C). Note the narrow middle cerebellar 
peduncles.
Figure 2 Axial T2-fluid-attenuated inversion recovery (FLAIR) 
image of the brain, showing high signal in the middle cerebellar 
peduncles, in a case of fragile X tremor-ataxia syndrome 
(FXTAS).
impact of next-generation sequencing is such that 
targeted searches for known gene mutations (other than 
in family members, where this is already fully charac-
terised) may soon become obsolete. Candidate gene 
testing is still available, for example, in the UK via the 
UK Genetics Testing Network (https:// ukgtn. nhs. uk). 
Next-generation sequencing panels allow the search for 
a wider array of ‘ataxia genes’, available from specialist 
genetic laboratories (Oxford and Sheffield, in the UK). 
When the diagnosis remains elusive, clinicians should 
consider exome or whole-genome sequencing.
When undertaking genetics tests, even for diagnostic 
purposes, clinicians should counsel people with ataxia 
about the potential implications of a positive result for 
other family members. Genetic counselling services 
should be made available for asymptomatic relatives 
who wish to be tested, after identifying a pathological 
genetic variant in a patient with progressive ataxia. There 
may also be important implications on the reproductive 
choices that patients and at-risk relatives make, based on 
this knowledge, including in relation to prenatal testing 
and preimplantation genetic diagnosis.5 These services 
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Figure 3 Axial T2-weighted MRI of the brain, showing 
haemosiderin deposition around the medulla and cerebellum, in 
a case of superficial siderosis. (Gradient echo (GRE)/T2* imaging 
would have demonstrated these changes more vividly.)
Figure 4 Axial T2-weighted MRI of the brain in a case of 
autosomal recessive spastic ataxia of Charlevoix-Saguenay 
(ARSACS) showing pontine hypointense (‘tigroid’) stripes.
Figure 5 Axial T2-weighted MRI of the brain in a case of 
hereditary spastic paraplegia 7 (SPG7) showing hyperintensity 
of the dentate nuclei (arrowed).
Figure 6 Sagittal T1-weighted MRI of the brain and upper 
cervical cord in a 26-year-old woman with ataxia. There is 
relative preservation of the brainstem and cerebellum, but 
thinning of upper cervical cord. (Friedreich’s ataxia (FRDA) was 
confirmed in her genetically.)
are delivered by clinical genetics services, in liaison with 
specialist obstetrics/prenatal units.
Next-generation sequencing is already showing great 
promise for investigating patients with ataxia. There 
are already ‘ataxia panels’ using parallel sequencing 
technology but they are limited because they seek only 
known (ataxia) genes.6 Exome sequencing and whole-ge-
nome sequencing (the approach adopted by the 100,000 
Genomes Project) are increasingly used in clinical prac-
tice, and will probably make major contributions to our 
knowledge of the underlying genetic factors and mecha-
nisms causing ataxia, as well as expanding our diagnostic 
acumen. A critical issue with these ‘novel’ techniques 
is the generation of data in the form of variants of 
unknown significance, and the interpretation of ‘results’ 
needs significant bioinformatics input. Technologically, 
too, next-generation sequencing is still not sufficiently 
reliable to identify large-scale genomic rearrangements, 
including nucleotide expansions with certainty (or with 
precision regarding the number of repeats, in the case of 
expansions). Thus, at present, we need a combination of 
conventional and novel techniques to investigate familial 
ataxia.
Dominant ataxias
There are over 40 dominant currently identified SCAs, 
some of which may be limited to a small number of 
families or geographical areas.7 SCAs 1, 2 and 3 can be 
‘complicated’ by the co-occurrence of cognitive decline, 
slow saccades, ophthalmoplegia, pyramidal/extrapyra-
midal signs and neuropathy. Patients with SCA7 usually 
also have macular degeneration and blindness. Some 
forms—including SCA7 and dentato-rubro-pallido-luy-
sian atrophy—have extreme repeat expansion instability, 
and hence a tendency for severe anticipation (particu-
larly when paternally inherited). SCA6 (a relatively 
‘pure’ form of SCA) typically has stable CAG repeat 
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Table 3 Diagnostic investigations in adults
Primary care Serum urea and electrolytes, serum 
creatinine, full blood count
ESR/C-reactive protein
Liver enzymes, serum γ-GT, thyroid function 
tests
Vitamin B12
Serum folate, plasma glucose, chest X-ray
Secondary care 
(first line)
αFP
Blood film
Caeruloplasmin/copper
Coeliac disease screen, serum creatine 
kinase
Genetic tests for Friedreich’s ataxia, SCA 
1, 2, 3, 6, 7 (12, 17) and fragile X tremor-
ataxia syndrome
Lactate
Lipid-adjusted vitamin E and lipoproteins
Lumbar puncture (cells, protein, glucose, 
cytology, oligoclonal bands, lactate, ferritin)
MR scan of brain and cervical spine
Anti-Hu/Yo and other paraneoplastic 
antibodies
Anti-GAD antibody
Anti-voltage-gated calcium channel 
antibody
CT scan of chest, abdomen, pelvis
14-3-3 and other proteins in CSF (prion 
diseases)
Secondary care 
(second line)
Cholestanol
Plasma oxysterols
Bile acids
Coenzyme Q10 (ubiquinone)
Electroencephalography
Very-long-chain fatty acids
Muscle biopsy
Ophthalmology/optical coherence 
tomography
Peripheral nerve conduction studies
Phytanic acid
Remaining genetic tests (next-generation 
sequencing)
Total body PET scan
White cell enzymes
CSF, cerebrospinal fluid; ESR, erythrocyte sedimentation rate; αFP, alpha-fetoprotein; GAD, glutamic acid decarboxylase; γ-GT, gamma-glutamyltransferase; 
PET, positron emission tomography; SCA, spinocerebellar ataxia.
Figure 7 How often is a genetic cause of progressive ataxia identified? Dx, diagnosis; ANO10, ANO10-associated ataxia; AOA1/
AOA2, ataxia with oculomotor apraxia types 1 and 2; AT, ataxia-telangiectasia; EA2, episodic ataxia type 2; FRDA, Friedreich’s ataxia; 
FXTAS, fragile X tremor-ataxia syndrome; Mit, mitochondrial cytopathy; SCA6, spinocerebellar ataxia type 6; SPG7, hereditary spastic 
paraplegia 7.
expansions during meiosis. The causative gene of SCA6 
is also implicated in another form of dominant ataxia, 
episodic ataxia type 2, and a form of familial hemiplegic 
migraine (both of which, like SCA6, manifest with 
progressive ataxia, usually after 50 years). SCA6/episodic 
ataxia type 2 is the most common dominant ataxia in the 
British Isles (see figure 7). The genetic mutations under-
pinning the SCAs are diverse, and include trinucleotide 
repeat expansions (eg, SCAs 1–3 and 6), non-trinucle-
otide repeat expansions (eg, SCA10, where there is an 
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intronic pentanucleotide repeat expansion of ATXN10), 
deletions/insertions and missense/nonsense mutations.
Recessive ataxias
Friedreich’s ataxia is the most common inherited 
ataxia in Caucasian populations, with a prevalence 
of around 1 per 20 000–50 000. Spastic paraplegia 
7 (SPG7), a classical cause of hereditary spastic para-
paresis, is the next most common recessive ataxia in 
the UK.8 Patients with SPG7 may have only minimal 
spasticity. Spastic ataxia is also a feature of autosomal 
recessive spastic ataxia of Charlevoix-Saguenay. In 
terms of frequency, Friedreich’s ataxia and SPG7 are 
followed by ataxia with oculomotor apraxia type 2 and 
ataxia-telangiectasia (which presents less commonly 
in adulthood). MRI may provide useful clues on the 
genetic cause (table 2). Clues to ataxia-telangiectasia 
(and ataxia with oculomotor apraxias) include a high 
serum alpha-fetoprotein and creatine kinase, and a low 
serum albumin. Optical coherence tomography can 
provide support for a diagnosis of autosomal recessive 
spastic ataxia of Charlevoix-Saguenay.
Despite the growing emphasis on next-generation 
sequencing in helping to diagnose inherited ataxia,6 
accurate clinical phenotyping (incorporating relevant 
laboratory data) remains important. This is especially 
so when there are ‘variants of uncertain significance’: 
knowledge and experience must then supplement the 
bioinformatics pipeline. ‘Deep phenotyping’ is an 
emerging field where promising biomarkers are used 
to target genetic testing (which is still expensive). 
For example, retinal fibre layer thickening (identified 
using optical coherence tomography) appears to be 
a sensitive and specific indicator of autosomal reces-
sive spastic ataxia of Charlevoix-Saguenay.9 Periph-
eral electrophysiology may also help define the cause 
of (recessive) ataxias. There are four categories (after 
eliminating Friedreich’s ataxia) based on:
1. The absence of neuropathy (mutations in SYNE1, 
ANO10 and ADCK3).
2. The presence of a pure sensory neuronopathy (mutations 
in POLG1, AVED and RFC1).
3. The presence of an axonal sensorimotor neuropathy 
(ataxia with oculomotor apraxia types 1 and 2, and cere-
brotendinous xanthomatosis).
4. The presence of a demyelinating neuropathy (autosomal 
recessive spastic ataxia of Charlevoix-Saguenay).10
relative frequency of genetic forms of ataxia
Figure 7 shows data from two specialist ataxia centres 
in Sheffield and Dublin, giving an insight to the rela-
tive frequencies of the different inherited ataxias in the 
British Isles. The data also suggest the likelihood of 
making a specific diagnosis in the specialist setting.11 
12 However, these proportions vary with geography, 
reflecting founder gene mutations on different 
populations.
Immunological studies, including testing, for coeliac disease
Autoimmunity is increasingly recognised as a cause of 
progressive cerebellar ataxia. A cohort of patients from 
Sheffield with ataxia and positive antigliadin anti-
bodies (a serological marker of gluten sensitivity and 
coeliac disease) is perhaps the best studied.13 In this 
series, 25% of all sporadic cases were diagnosed with 
gluten ataxia, although in other centres the proportion 
recognised is considerably lower.11 Given Sheffield’s 
interest and expertise, testing included serum antigli-
adin IgG and IgA, antiendomysium and antitransglu-
taminase antibodies (including TG6 antibodies) and 
duodenal biopsy. Only half of patients with gluten 
ataxia have small bowel enteropathy (coeliac disease) 
and so antigliadin antibodies are essential for diag-
nosing the remainder. Antibodies against transglutam-
inase type 6 (TG6) are a potentially useful biomarker 
of gluten ataxia, and such testing may become 
commercially viable shortly ( zedira. com). Mutations 
in the transglutaminase 6 gene (TGM6) meanwhile 
are associated with a dominant SCA (SCA35), further 
supporting a role for TG6 in cerebellar functioning. 
There is also a well-characterised form of progres-
sive myoclonic ataxia (of Ramsay Hunt) in patients 
with coeliac disease; most have refractory coeliac 
disease and need aggressive immunosuppression and 
chemotherapy.
Other immune-mediated ataxias include parane-
oplastic spinocerebellar degeneration, anti-glutamic 
acid decarboxylase-associated ataxia, and ataxia asso-
ciated with several other antibodies (anti-voltage-gated 
calcium channel, dipeptidyl-peptidase-like protein 6 
(DPPX), and so on). These frequently present acutely 
or subacutely. Taken together, these observations raise 
the possibility that immunity plays a critical role in 
causing cerebellar injury in some patients with ataxia. 
Thus, immune modulation may have a possible role 
in stabilising their disease and preventing progression.
The diagnostic pathway is summarised in the info-
graphic (figure 8).
Management
Neurologists traditionally have taken a nihilistic view 
to managing ataxia, as with many other neurodegener-
ation diseases. However, this is no longer justified. In 
addition to rehabilitation therapies, there are specific 
complications of ataxia to seek and address. These 
interventions can significantly alleviate the problems 
of progressive ataxia and prevent complications, 
which are even potentially life threatening. Finally, 
there are some rare but treatable conditions that need 
identifying early. An enthusiastic and well-informed 
clinician can provide valuable support to a patient 
with ataxia. Participation in research can be important 
for patients and, when appropriate, they should be 
offered opportunities for this at each clinical review ( 
www. clinicaltrials. gov and www. ataxia. org. uk). When 
a patient with ataxia approaches end of life, specialist 
 o
n
 3 June 2019 by guest. Protected by copyright.
http://pn.bmj.com/
Pract N
eurol: first published as 10.1136/practneurol-2018-002096 on 2 M
ay 2019. Downloaded from
 
203de Silva RN, et al. Pract Neurol 2019;19:196–207. doi:10.1136/practneurol-2018-002096
Review
Figure 8 Infographic 1: The Diagnostic Pathway
palliative care services should be involved to help 
address their specific needs.
Medical interventions
Treatable ataxias
Ataxias that are treatable are rare, except for gluten 
ataxia and other immune-mediated ataxias. In people 
with ataxia associated with antigliadin (and possibly 
more specific antibodies), we recommend a gluten-free 
diet even in the absence of enteropathy.14 The antibody 
titres should be repeated every 6 months to confirm 
their elimination (by strict adherence to the diet). Note, 
however, that the symptoms may not stabilise or improve 
for up to a year.
Ataxia with vitamin E deficiency mimics Friedreich’s 
ataxia (clinically and on MRI) and can be confirmed 
genetically. The serum vitamin E concentration is 
significantly low but should be tested as ‘lipid-adjusted 
vitamin E’, as free vitamin E concentrations are unre-
liable and potentially misleading. Malabsorption 
of vitamin E, including in abetalipoproteinaemia, 
can result in a similar phenotype. Patients may need 
replacement doses of up to 1500 mg/day.15
Ataxia with CoQ10 (or ubiquinone) deficiency is 
probably under-recognised. It is a recessively inherited 
disorder (ADCK3 mutations) where patients have a 
low concentration of CoQ10 in skeletal muscle.16 Its 
severity is variable and some people have seizures and 
mild mental retardation. CoQ10 supplementation can 
potentially improve the ataxic symptoms, although not 
in everyone (and the exact form and dose of CoQ10 
remains uncertain).17 18 Patients with mutations in 
APTX (AOA1) and ANO10 can develop secondary 
CoQ10 deficiency, and supplementation may also help 
them.19
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Figure 9 Infographic 2: Symptom Management, including Multidisciplinary Team Input
Patients with cerebrotendinous xanthomatosis may 
develop chronic diarrhoea in infancy, and cataracts 
in the first decade. There may be visible deposits 
of cholestenol in tendons. If confirmed (usually 
biochemically), then chenodeoxycholic acid treat-
ment can stabilise or partially reverse the symptoms, 
or (if given very early) may even help the neurolog-
ical complications.20 21
Niemann-Pick type C is a multisystem disorder caused 
by the accumulation of cholesterol and glycosphin-
golipids in the brain and other organs. Consequently, 
patients may develop splenomegaly and hepatomegaly 
as well as ataxia. There may be a vertical supranu-
clear gaze palsy, sometimes with dystonia, myoclonus, 
epilepsy and cognitive decline. The diagnosis can be 
challenging, especially in (atypical) cases that present 
later in life, and biopsy (of bone marrow and skin) does 
not always give a definitive answer.22 Genetic testing for 
the two causative genes (NPC1 implicated in 95% and 
NPC2 implicated in 5%) may be more reliable. Plasma 
oxysterols and bile acid measurements may prove to be 
useful and inexpensive screening tools.23–25 Miglustat is 
an approved disease-modifying therapy for patients with 
Niemann-Pick type C.26 27
There are other treatable causes of ataxia, but these 
typically present in children and are usually managed 
in paediatric practice. These include CoQ10 (or 
ubiquinone) deficiency, hypobetalipoproteinaemia, 
Hartnup disease, biotinidase deficiency and pyruvate 
dehydrogenase deficiency. Glucose transporter 1 
deficiency often presents with paroxysmal movement 
disorders, spasticity and ataxia, and its onset can be 
delayed. A ketogenic diet is effective in treating the 
associated epilepsy but perhaps is less effective in 
helping the gait difficulties.28
Symptomatic treatments
The infographic summarises the potential symptoms 
that neurologists may need to address (figure 9). The 
treatment ‘strategies’ are frequently derived from 
other neurological conditions with similar symp-
toms, and generally work equally well. The approach 
to treating spasticity and bladder symptoms, for 
example, is the same as for people with multiple scle-
rosis.29 30 The assessment and management of these 
complications are best done by involving therapy 
specialists, and multidisciplinary team working can 
greatly enhance patient care. Speech and language 
therapy input is essential throughout the patient 
journey, from monitoring swallowing function in the 
early stages and providing helpful hints on avoiding 
complications, to planning percutaneous gastrostomy 
feeding.31 Note that almost all these interventions to 
manage patients with ataxia are non-evidence based, 
and will probably never be studied in high-quality 
randomised controlled trials.
The impact of cerebellar disease on cognition 
is not widely known but can significantly impact 
on morbidity. Such ‘remote’ effects of cerebellar 
dysfunction can include subcortical frontal impair-
ments, affecting personality, behaviour and judge-
ment.32 Mental health complications (anxiety, 
depression) may exacerbate people’s sense of isola-
tion and fear of the future. These symptoms often 
accompany sleep disorders and fatigue but are 
poorly recognised (according to Ataxia UK’s survey). 
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The management of cardiac complications is espe-
cially important in Friedreich’s ataxia; patients need 
regular ECGs and (ideally) echocardiograms to 
detect cardiomyopathy developing.33–35 Echocardi-
ography may show concentric left ventricular hyper-
trophy (possibly in over half of cases, especially in 
those of early onset). With disease progression, the 
hypertrophy regresses, resulting in a thin and dilated 
left ventricle. Serum troponin may be asymptomat-
ically elevated (in the absence of arrhythmia or an 
acute coronary syndrome), and it may help to have 
baseline values for future comparison. It is essential 
to involve an interested and knowledgeable cardi-
ologist with experience of the care of Friedreich’s 
ataxia, initially to advise on medication to treat the 
cardiomyopathy and heart failure, and later for the 
management of arrhythmias.
Episodic ataxia type 2 is characterised by periods 
of cerebellar dysfunction lasting for hours or days, 
sometimes with migraine, and rarely epilepsy. Later 
in life, the ataxia becomes progressive, and MRI may 
show cerebellar atrophy.36 Attacks can be precipitated 
by stress, exertion, caffeine and alcohol, and patients 
should be counselled appropriately. Acetazolamide 
remains the mainstay of treatment but carries a risk of 
renal calculi and (more commonly) of paraesthesia. 
As well as good hydration, we recommend annual 
ultrasound scans of the urinary tract. Flunarizine 
and 4-aminopyridine, a potassium channel blocker, 
can also help but (like acetazolamide) they are not 
licensed in the UK to use in episodic ataxia type 
2.37 Dichlorphenamide is extremely effective and 
well tolerated but is currently too expensive to use 
routinely. Having seizures is a contraindication to 
using 4-aminopyridine.
Allied health professional interventions
The multidisciplinary team is clearly important 
in evaluating and managing patients with ataxia. 
Speech and language therapy (for both communi-
cation and swallowing), occupational therapy and 
physiotherapy can each make important contribu-
tions at different stages of the patient journey. It 
can be difficult to access interested and knowledge-
able therapists in the community, and this type of 
expertise is rare outside of specialist ataxia clinics. 
The guidelines have sections in each of these fields, 
giving comprehensive advice on the types of assess-
ments and interventions that need to be done, and 
may serve as an educational resource to accom-
pany referrals to community therapy teams. In our 
experience, the nurturing of local ‘champions’ in 
ataxia management (frequently a therapy colleague 
working in a district general hospital) can generate 
enthusiasm and help develop local expertise; in time 
these therapists frequently become effective access 
points for services for patients and their carers.
Reviews and monitoring
Patients with progressive ataxias should be offered 
6–12 monthly reviews, ideally by a general neurolo-
gist or (where available) an ataxia specialist (neurolo-
gist or nurse). There are also services specifically for 
adults and children with ataxia-telangiectasia, where 
specialist input (again by multiprofessional teams) 
can tackle the complications associated with this 
condition, including cancer predisposition, immuno-
deficiency and lung disease. Patients require regular 
review to identify any new symptoms early that may 
need treatment, and for patients to take advantage of 
advances in diagnostics and any new available treat-
ments. In addition, those with no established cause 
for their ataxia can undergo thorough and repeated 
review of the clinical features and investigation 
results, which sometimes leads to a clearer diagnosis.
Patient support groups
Patients and their families should be encouraged 
to contact patient support groups, such as Ataxia 
UK. When a family first receives the diagnosis of 
progressive ataxia, patients are usually not heard of 
the condition or come across other people with it. 
Support from patient organisations can therefore be 
particularly important at this stage. The possibility 
of meeting others in the same situation, receiving 
emotional support and information, and the oppor-
tunity to learn of research developments (as well as 
taking part in research projects) can all help.
Palliative care
Given that most progressive ataxias are incurable, 
there are strikingly few published studies on their 
palliation and end-of-life care. Many patients with 
progressive ataxia have a normal life expectancy but 
some forms (eg, multiple systems atrophy type C) can 
progress rapidly, with a shortened life. The recom-
mendations in these guidelines are drawn from the 
wider field of progressive neurological conditions.
We suggest that patients discuss advanced care 
planning at the appropriate time. Patients with 
intractable and/or distressing physical symptoms 
may benefit from referral for specialist palliative 
care, which might also help those with complex 
social, psychological or spiritual needs. The time 
for planning end-of-life care is when the clinician 
answers ‘No’ to the ‘surprise question’—‘Would 
you be surprised if this patient died in the next 12 
months?’—as well there being generic and specific 
(for ataxia) indicators that the patients have reached 
the terminal phase of their illness. Management in 
this phase should be geared towards enabling a ‘good 
death’: being treated as an individual, with dignity 
and respect, without pain or other distressing symp-
toms, in familiar surroundings, and in the company 
of close friends and family.38
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Key points
 ► Progressive ataxia in adults is heterogeneous and can 
be difficult to diagnose.
 ► Brain imaging, ideally with MRI, is essential.
 ► Rapidly progressive ataxia warrants urgent 
investigation (particularly to exclude underlying 
malignancy).
 ► Next-generation sequencing is enabling many more 
‘idiopathic’ ataxias to be given a genetic cause.
 ► Immunity may be an under-recognised (and potentially 
reversible) cause of progressive ataxia.
 ► The complications accompanying certain ataxias (eg, 
Friedreich’s ataxia with cardiomyopathy and diabetes) 
require active monitoring and management.
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